Neurocrine Biosciences | NBIX - Selling And Administration Expenses

Stock Price
137.13
Daily Change
1.07 0.79%
Monthly
0.84%
Yearly
-8.64%
Q1 Forecast
131.87

Neurocrine Biosciences reported $291.6M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amgen USD 1.7B 9M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Exelixis USD 103.13M 9.8M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Prothena USD 13.24M 2.67M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Repligen USD 73.66M 2.43M Sep/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025